Bilobil forte, 80 mg capsules 20 pcs

Visual impairment, Concussion and other brain injuries, Attention and memory impairment, Stroke sequelae, Prevention of thrombosis, Impaired cerebral circulation, Visual impairment, Headache, Hearing impairment

– Symptomatic treatment for adult cognitive impairment.

– As part of the complex therapy of vertigo of vestibular origin as an adjunctive treatment in addition to vestibular rehabilitation.

– Symptomatic treatment for tinnitus (ringing or tinnitus).

Active ingredient

Composition

1 capsule contains:

Active ingredient:

Ginkgo biloba leaf extract 80.00 mg (Ginkgo biloba leaf extract dry*)

Supplementary substances:

Liquid dextrose [dextrose, oligo- and polysaccharides], lactose monohydrate, corn starch, talcum, colloidal silicon dioxide, magnesium stearate

Composition of the hard gelatin capsule (body and cap):

Iron oxide black dye (E172), iron oxide red dye (E172), titanium dioxide (E171), azorubin dye (E122), gelatin

*Ginkgo biloba leaf extract dried from Ginkgo biloba leaves (Ginkgo biloba L., family Ginkgoaceae, folium).

Ratio of the amount of medicinal plant raw materials to the amount of the initial extract: 35 – 67:1. The extractant is acetone/water.

How to take, the dosage

Orally. Capsules should be swallowed whole with a small amount of water, regardless of the time of meals.

Simptomatic treatment of cognitive disorders in adults

Take 1 capsule 2-3 times daily.

Comprehensive therapy of vertigo of vestibular origin and symptomatic treatment of tinnitus (tinnitus or tinnitus)

Adults take 1 capsule 2 times a day (morning and evening).

The first signs of improvement usually appear after 1 month.

Course of treatment at least 3 months (especially for elderly patients). The repeated course is possible after consulting the doctor.

If the drug was missed or an insufficient amount was taken, its subsequent administration should be carried out as indicated in these instructions, without any changes.

Interaction

It is not recommended to use Bilobil® forte in patients who regularly take acetylsalicylic acid, anticoagulants (direct and indirect action), as well as thiazide diuretics, tricyclic antidepressants, anticonvulsants, gentamicin. There may be single cases of bleeding in patients simultaneously taking medications that reduce blood clotting; the causal relation of these bleedings with taking Ginkgo biloba products has not been confirmed.

When used with hypotensive agents, potentiation of the antihypertensive effect is possible.

Special Instructions

Performulation in patients with epilepsy, with arterial hypotension.

Performulation with caution in patients with epilepsy, with arterial hypotension.

Controlled in patients under 18 years of age (effectiveness and safety have not been studied)

Performulation with caution in patients with epilepsy, with arterial hypotension.

Do not exceed the recommended doses of Bilobil® forte.

If a hypersensitivity reaction develops, the use of the drug should be discontinued. Before surgery, the physician should be informed about the use of Bilobil® forte.

In case of frequent sensations of dizziness and tinnitus, a physician should be consulted. In case of a sudden worsening or loss of hearing, consult a physician immediately. Patients with bleeding disorder (hemorrhagic diathesis) and patients receiving anticoagulant therapy should consult a physician before starting therapy with Bilobil® forte.

It is not recommended to use Bilobil® forte with ethanol.

An epileptic seizure may occur in patients with Ginkgo biloba.

Special information about the excipients

1 capsule of Bilobil® forte contains 196 mg of digestible carbohydrates (glucose, lactose, starch), corresponding to 0.0163 bread units (BE), the maximum daily dose (3 capsules) corresponding to 0.049 BE.

Bilobil® Forte contains the dye azorubin (E122) which can cause allergic reactions.

When taking Bilobil® Forte, extreme caution should be exercised while driving potentially dangerous activities requiring high concentration and psychomotor reaction rate (including driving vehicles and operating moving mechanisms) and in case of adverse reactions including dizziness should be avoided.

Synopsis

Solid gelatin capsules № 2, the body and the cap are pink. The contents of the capsules – powder from light brown to dark brown in color with particles of darker color. The presence of small lumps is allowed.

Contraindications

Hypersensitivity to the components of the drug, decreased blood clotting, erosive gastritis, gastric ulcer and duodenal ulcer in the acute stage, acute cerebral circulatory disorders, acute myocardial infarction, pregnancy, lactation, children under 18 years old (efficacy and safety have not been studied), lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome, because Bilobil® forte contains lactose.

Side effects

classification of frequency of side effects according to World Health Organization (WHO) recommendations:

very frequently ≥1/10

often ≥ 1/100 to < 1/10

infrequently from ≥ 1/1000 to < 1/100

rarely from ≥ 1/10000 to < 1/1000

very rarely from < 1/10000

frequency is unknown cannot be estimated from available data.

In each group the adverse effects are presented in decreasing order of severity.

From the digestive system:

very rarely: nausea, vomiting, diarrhea.

From the nervous system:

very rarely: headache, dizziness, insomnia.

Allergic reactions:

very rarely: hyperemia, edema, skin itching.

With the hemostasis system:

very rare: decreased blood clotting. There are reports on the occurrence of bleeding when prolonged use of Ginkgo biloba products in patients who simultaneously took agents that reduce blood clotting.

Senses:

frequency unknown: hearing disorders.

If any adverse events occur, the drug should be discontinued and the patient should consult a physician.

Overdose

To date, no cases of overdose of Bilobil® forte have been reported. In case of overdose the treatment is symptomatic.

Pregnancy use

Bilobil® forte is contraindicated in pregnancy and during breastfeeding due to insufficient clinical data.

Similarities